Suppr超能文献

凝血酶诱导的血小板表面糖蛋白Ib-IX集中需要肌动蛋白组装和肌球蛋白II激活。

Thrombin-induced GPIb-IX centralization on the platelet surface requires actin assembly and myosin II activation.

作者信息

Kovacsovics T J, Hartwig J H

机构信息

Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.

出版信息

Blood. 1996 Jan 15;87(2):618-29.

PMID:8555484
Abstract

In resting platelets, the GPIb-IX complex, the receptor for the von Willebrand factor (vWF), is linked to underlying actin filaments by actin-binding protein (ABP-280). Thrombin stimulation of human platelets leads to a decrease in the surface expression of the GPIb-IX complex, which is redistributed from the platelet surface into the open canalicular system (OCS). Because the centralization of GPIb-IX is inhibited by cytochalasin, it is believed to be linked to actin cytoskeletal rearrangements that take place during platelet activation. We have further characterized the mechanism of GPIb-IX centralization in platelets in suspension. Following thrombin stimulation, GPIb-IX shifts from the membrane skeleton of the resting cell to the cytoskeleton of the activated cell in a reaction sensitive to cytochalasin B. The cytoskeletal association of GPIb-IX involves ABP-280, as it correlates with the incorporation of ABP-280 into the activated cytoskeleton and because no dissociation of the ABP-280/GPIb-IX complexes is detected after thrombin activation. However, the incorporation of GPIb-IX into the cytoskeleton is complete within 1 minute, whereas GPIb-IX centralization requires 5 to 10 minutes for completion. The movement of GPIb-IX to the cytoskeleton of activated platelets is therefore necessary, but not sufficient for GPIb-IX centralization. Blockage of cytosolic calcium increases induced by thrombin by loading with the cell permeant calcium chelator Quin-2 AM inhibited GPIb-IX centralization by 70%, but did not prevent its association with the activated cytoskeleton. Quin-2 loading did, however, decrease the incorporation of myosin II into the activated cytoskeleton. The role of myosin II was further probed using the myosin light chain kinase (MLCK) inhibitor wortmannin. Wortmannin prevents myosin II association to the activated cytoskeleton and inhibits GPIb-IX centralization by 50%, without affecting actin assembly or the association of GPIb-IX to the cytoskeleton. Only micromolar concentrations of wortmannin, high enough to inhibit MLCK, prevent GPIb-IX centralization. These results indicate that thrombin-induced GPIb-IX centralization requires a minimum of two steps, one associating GPIb-IX to the activated cytoskeleton and the second requiring myosin II activation. The involvement of myosin II implies that GPIb-IX/ABP-280 complexes, linked to actin filaments, are pulled into the cell center, and that platelets may exert contractile tension on vWF bound to its receptor.

摘要

在静息血小板中,血管性血友病因子(vWF)的受体糖蛋白Ib-IX复合物(GPIb-IX)通过肌动蛋白结合蛋白(ABP-280)与下方的肌动蛋白丝相连。凝血酶刺激人血小板会导致GPIb-IX复合物的表面表达减少,该复合物从血小板表面重新分布到开放小管系统(OCS)中。由于细胞松弛素可抑制GPIb-IX的集中化,因此认为它与血小板激活过程中发生的肌动蛋白细胞骨架重排有关。我们进一步研究了悬浮血小板中GPIb-IX集中化的机制。凝血酶刺激后,GPIb-IX在对细胞松弛素B敏感的反应中从静息细胞的膜骨架转移到激活细胞的细胞骨架。GPIb-IX与细胞骨架的结合涉及ABP-280,因为它与ABP-280并入激活的细胞骨架相关,并且在凝血酶激活后未检测到ABP-280/GPIb-IX复合物的解离。然而,GPIb-IX并入细胞骨架在1分钟内完成,而GPIb-IX集中化需要5至10分钟才能完成。因此,GPIb-IX向激活血小板细胞骨架的移动是必要的,但不足以实现GPIb-IX的集中化。通过用细胞渗透性钙螯合剂喹啉-2 AM(Quin-2 AM)加载来阻断凝血酶诱导的胞质钙增加,可使GPIb-IX集中化受到70%的抑制,但并不阻止其与激活的细胞骨架结合。然而,喹啉-2加载确实减少了肌球蛋白II并入激活的细胞骨架。使用肌球蛋白轻链激酶(MLCK)抑制剂渥曼青霉素(wortmannin)进一步探究了肌球蛋白II的作用。渥曼青霉素可阻止肌球蛋白II与激活的细胞骨架结合,并使GPIb-IX集中化受到50%的抑制,而不影响肌动蛋白组装或GPIb-IX与细胞骨架的结合。只有微摩尔浓度的渥曼青霉素(高到足以抑制MLCK)才能阻止GPIb-IX集中化。这些结果表明,凝血酶诱导的GPIb-IX集中化至少需要两个步骤,一个是将GPIb-IX与激活的细胞骨架结合,另一个是需要肌球蛋白II激活。肌球蛋白II的参与意味着与肌动蛋白丝相连的GPIb-IX/ABP-280复合物被拉向细胞中心,并且血小板可能对与其受体结合的vWF施加收缩张力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验